Amélie Boulais

Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.

Find out about the five top trends that will shape biopharma manufacture in 2021.

What have we learned from the pandemic and how can we address the coming challenges?

There is a promising pipeline of vaccine candidates, but what happens if the frontrunners fail?

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.

Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.

As the world grasps the severity of the ongoing pandemic, we must ask how we can accelerate vaccine development safely.